

**POLICY:** Enzyme Replacement Therapy – Mepsevii Utilization Management Medical Policy

- Mepsevii® (vestronidase alfa-vjbc intravenous infusion – Ultragenyx)

**EFFECTIVE DATE:** 1/1/2021

**LAST REVISION DATE:** 04/15/2026

**COVERAGE CRITERIA FOR:** All Aspirus Medicare Plans

---

### **OVERVIEW**

Mepsevii, a lysosomal beta glucuronidase (GUS), is indicated for the treatment of **Mucopolysaccharidosis type VII** ([MPS VII], Sly syndrome).<sup>1</sup> It is produced in a Chinese hamster ovary cell line via recombinant DNA technology. It has the same amino acid sequence as human GUS and catabolizes accumulated glycosaminoglycans in lysosomes in affected tissues.

### **Disease Overview**

MPS VII or Sly syndrome is an extremely rare lysosomal storage disorder characterized by deficient GUS activity.<sup>2</sup> In MPS VII, the partially catabolized glycosaminoglycans, chondroitin sulfate, dermatan sulfate, and heparin sulfate accumulate in the lysosomes, ultimately leading to the signs and symptoms of the disease.<sup>2,3</sup> The onset, severity, and rate of progression of MPS VII is heterogeneous. Patients may present at birth with hydrops fetalis and only survive a few months while others may have milder disease and survive into their 40s.<sup>2</sup> However, most patients have mental retardation, hepatosplenomegaly, and musculoskeletal issues including short stature, coarse facial features, loss of range of motion, restricted mobility, scoliosis, and kyphosis. The diagnosis of MPS VII is established by demonstrating deficient GUS activity in leukocytes, fibroblasts, or serum; or by genetic testing.<sup>3</sup> Treatment for MPS VII includes enzyme replacement therapy with Mepsevii and hematopoietic stem cell transplantation.<sup>2,4</sup>

### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Mepsevii. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Mepsevii as well as the monitoring required for adverse events and long-term efficacy, approval requires Mepsevii to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Mepsevii is recommended in those who meet the following criteria:

#### FDA-Approved Indication

- 1. Mucopolysaccharidosis Type VII (Sly Syndrome).** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A) The diagnosis is established by ONE of the following (i or ii):**
    - i.** Patient has a laboratory test demonstrating deficient beta-glucuronidase activity in leukocytes, fibroblasts, or serum; OR
    - ii.** Patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic glucuronidase (*GUS*) gene variants; AND
  - B) Mepsevii is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.**

**Dosing.** Each dose must not exceed 4 mg/kg administered intravenously no more frequently than once every 2 weeks.

#### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Mepsevii is not recommended in the following situations:

- 1.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

#### REFERENCES

1. Mepsevii® intravenous infusion [prescribing information]. Novato, CA: Ultragenyx; December 2020.
2. Montano AM, Lock-Hock N, Steiner RD, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). *J Med Genet.* 2016;53:403-418.
3. Tomatsu S, Montano AM, Dung VC, et al. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly syndrome). *Hum Mutat.* 2009;30:511-519.
4. Grant CL, Lopez-Valdez J, Marsden D, Ezgu F. Mucopolysaccharidosis type VII (Sly syndrome) – what do we know? *Mol Genet Metab.* 2024;141(3):108145.

#### HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	04/12/2023
Annual Revision	<b>Mucopolysaccharidosis Type VII (Sly Syndrome):</b> Confirmation of a genetic mutation in the glucuronidase gene was revised to more specifically state, “genetic testing demonstrating biallelic pathogenic or likely pathogenic glucuronidase gene variants”.	04/24/2024
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	09/16/2024
Annual Revision	No criteria changes.	04/16/2025
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	09/15/2025
Annual Revision	No criteria changes.	04/15/2026